Plasma From Recovered COVID-19 Patients Inhibits Spike Protein Binding to ACE2 in a Microsphere-Based Inhibition Assay
Plasma From Recovered COVID-19 Patients Inhibits Spike Protein Binding to ACE2 in a Microsphere-Based Inhibition Assay
复制标题
DOI：
10.1093/infdis/jiaa508
复制
发表时间：
2020-12-15
影响因子：
6.4
通讯作者：
Smith, Stephen E. P.
中科院分区：
文献类型：
--
作者：
Gniffke, Edward P.;Harrington, Whitney E.;Smith, Stephen E. P.
我们提出了一种基于微球的流式细胞术测定，定量血浆抑制刺突蛋白与血管紧张素转换酶2结合的能力。来自22名从2019年轻度冠状病毒病（COVID-19）中康复并表达抗刺突蛋白三聚体免疫球蛋白G的患者的血浆抑制血管紧张素转换酶2-刺突蛋白结合的程度高于对照组。抑制程度与抗刺突蛋白免疫球蛋白G水平、假型慢病毒测定中的中和滴度以及疾病期间发热的存在相关。这种抑制测定可广泛用于在无细胞测定系统中定量从COVID-19恢复的患者或疫苗接受者的功能性抗体应答。
We present a microsphere-based flow cytometry assay that quantifies the ability of plasma to inhibit the binding of spike protein to angiotensin-converting enzyme 2. Plasma from 22 patients who had recovered from mild coronavirus disease 2019 (COVID-19) and expressed anti-spike protein trimer immunoglobulin G inhibited angiotensin-converting enzyme 2-spike protein binding to a greater degree than controls. The degree of inhibition was correlated with anti-spike protein immunoglobulin G levels, neutralizing titers in a pseudotyped lentiviral assay, and the presence of fever during illness. This inhibition assay may be broadly useful to quantify the functional antibody response of patients recovered from COVID-19 or vaccine recipients in a cell-free assay system.